These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19437022)

  • 1. Urocortin and corticotropin-releasing factor receptor 2 in human renal cell carcinoma: disruption of an endogenous inhibitor of angiogenesis and proliferation.
    Tezval H; Jurk S; Atschekzei F; Becker JU; Jahn O; Serth J; Kuczyk MA
    World J Urol; 2009 Dec; 27(6):825-30. PubMed ID: 19437022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of anti-angiogenic signaling pathways.
    Tezval H; Jurk S; Atschekzei F; Serth J; Kuczyk MA; Merseburger AS
    Prostate; 2009 Mar; 69(4):443-8. PubMed ID: 19058138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urocortin's inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2.
    Wang J; Xu Y; Xu Y; Zhu H; Zhang R; Zhang G; Li S
    Cancer Invest; 2008 May; 26(4):359-68. PubMed ID: 18443956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urocortin II gene is highly expressed in mouse skin and skeletal muscle tissues: localization, basal expression in corticotropin-releasing factor receptor (CRFR) 1- and CRFR2-null mice, and regulation by glucocorticoids.
    Chen A; Blount A; Vaughan J; Brar B; Vale W
    Endocrinology; 2004 May; 145(5):2445-57. PubMed ID: 14736736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation dependent expression of urocortin's mRNA and peptide in human osteoprogenitor cells: influence of BMP-2, TGF-beta-1 and dexamethasone.
    Tezval M; Tezval H; Dresing K; Stuermer EK; Blaschke M; Stuermer KM; Siggelkow H
    J Mol Histol; 2009 Oct; 40(5-6):331-41. PubMed ID: 19949969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urocortin affects migration of hepatic cancer cell lines via differential regulation of cPLA2 and iPLA2.
    Zhu C; Sun Z; Li C; Guo R; Li L; Jin L; Wan R; Li S
    Cell Signal; 2014 May; 26(5):1125-34. PubMed ID: 24518041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart.
    Brar BK; Jonassen AK; Egorina EM; Chen A; Negro A; Perrin MH; Mjøs OD; Latchman DS; Lee KF; Vale W
    Endocrinology; 2004 Jan; 145(1):24-35; discussion 21-3. PubMed ID: 12970163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urocortin 2 expression in the rat gastrointestinal tract under basal conditions and in chemical colitis.
    Chang J; Hoy JJ; Idumalla PS; Clifton MS; Pecoraro NC; Bhargava A
    Peptides; 2007 Jul; 28(7):1453-60. PubMed ID: 17586086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced mRNA expression level of corticotropin-releasing hormone-binding protein is associated with aggressive human kidney cancer.
    Tezval H; Atschekzei F; Peters I; Waalkes S; Hennenlotter J; Stenzl A; Becker JU; Merseburger AS; Kuczyk MA; Serth J
    BMC Cancer; 2013 Apr; 13():199. PubMed ID: 23607589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation.
    Hao Z; Huang Y; Cleman J; Jovin IS; Vale WW; Bale TL; Giordano FJ
    Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3939-44. PubMed ID: 18308934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of corticotropin releasing factor receptor 2 (CRFR2) in the human prostate. A new potential target for medical therapy of benign prostatic hyperplasia].
    Tezval H; Merseburger AS; Seidler M; Serth J; Kuczyk MA; Oelke M
    Urologe A; 2008 Sep; 47(9):1079-80, 1082-4. PubMed ID: 18670748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Over-expression of neuropeptide urocortin and its receptors in human allergic nasal mucosa.
    Kim TH; Lee SH; Lee HM; Lee SH; Lee SW; Kim WJ; Park SJ; Kim YS; Choe H; Hwang HY; Yoo IO
    Laryngoscope; 2007 Sep; 117(9):1513-8. PubMed ID: 17597629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Social isolation modulates corticotropin-releasing factor type 2 receptor, urocortin 1 and urocortin 2 mRNAs expression in the cardiovascular system of prairie voles.
    Pournajafi-Nazarloo H; Partoo L; Sanzenbacher L; Esmaeilzadeh M; Paredes J; Hashimoto K; Azizi F; Carter CS
    Peptides; 2009 May; 30(5):940-6. PubMed ID: 19452635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for hormone recognition by the Human CRFR2{alpha} G protein-coupled receptor.
    Pal K; Swaminathan K; Xu HE; Pioszak AA
    J Biol Chem; 2010 Dec; 285(51):40351-61. PubMed ID: 20966082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1 and 2beta by the CRF/urocortin family of peptides.
    Brar BK; Chen A; Perrin MH; Vale W
    Endocrinology; 2004 Apr; 145(4):1718-29. PubMed ID: 14670995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer-Specific Loss of Urocortin 3 in Human Renal Cancer.
    Faraj Tabrizi P; Mohebbi Tafrechi A; Peters I; Atschekzei F; Kuczyk MA; Serth J; Tezval H
    Adv Ther; 2020 Jan; 37(1):288-299. PubMed ID: 31721113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible involvement of corticotropin-releasing factor receptor signaling on vascular inflammation.
    Inada Y; Ikeda K; Tojo K; Sakamoto M; Takada Y; Tajima N
    Peptides; 2009 Feb; 30(2):365-72. PubMed ID: 19026699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior.
    Bale TL; Picetti R; Contarino A; Koob GF; Vale WW; Lee KF
    J Neurosci; 2002 Jan; 22(1):193-9. PubMed ID: 11756502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urocortin suppresses endometrial cancer cell migration via CRFR2 and its system components are differentially modulated by estrogen.
    Owens GL; Lawrence KM; Jackson TR; Crosbie EJ; Sayan BS; Kitchener HC; Townsend PA
    Cancer Med; 2017 Feb; 6(2):408-415. PubMed ID: 28109061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urocortins are present in the rat testis.
    Lee S; Braden B; Kang SS; Rivier C
    Neuropeptides; 2011 Apr; 45(2):131-7. PubMed ID: 21256589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.